Theriva Biologics Inc (TOVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2016 | 09-2016 | 06-2016 | 03-2016 | 12-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -27,803 | -25,331 | -16,842 | -11,078 | -44,785 |
| Depreciation Amortization | 157 | 111 | 57 | 37 | 72 |
| Accounts payable and accrued liabilities | -2,420 | -171 | 143 | 184 | 3,417 |
| Other Working Capital | 7,148 | 8,478 | 6,307 | 3,817 | -5,536 |
| Other Operating Activity | -4,983 | -604 | -1,199 | 1,366 | 7,942 |
| Operating Cash Flow | $-27,901 | $-17,517 | $-11,534 | $-5,674 | $-38,890 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -569 | -199 | -45 | -44 | -501 |
| Investing Cash Flow | $-569 | $-199 | $-45 | $-44 | $-501 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 27,323 | 1,447 | 810 | N/A | 46,041 |
| Other Financing Activity | -616 | 0 | 0 | 0 | -3,357 |
| Financing Cash Flow | $26,707 | $1,447 | $810 | $N/A | $42,684 |
| Beginning Cash Position | 20,818 | 20,818 | 20,818 | 20,818 | 17,525 |
| End Cash Position | 19,055 | 4,549 | 10,049 | 15,100 | 20,818 |
| Net Cash Flow | $-1,763 | $-16,269 | $-10,769 | $-5,718 | $3,293 |
| Free Cash Flow | |||||
| Operating Cash Flow | -27,901 | -17,517 | -11,534 | -5,674 | -38,890 |
| Capital Expenditure | -569 | -199 | -45 | -44 | -501 |
| Free Cash Flow | -28,470 | -17,716 | -11,579 | -5,718 | -39,391 |